The first new drug to treat tuberculosis in more than 40 years, Bedaquiline is helping patients fight multidrug-resistant tuberculosis (MDR-TB) through its donation program – a public-private partnership between United States Agency for International Development (USAID) and Janssen Therapeutics of Johnson & Johnson.
